PAK7, actif, humain étiqueté GST, PRECISIO Kinase, recombinant, exprimé en cellules bactériulovirus infectées Sf9, > = 70% (SDS-PAGE), solution de glycérol aqueuse tamponnée

Code: k3268-10ug D2-231

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

PAK7 (p21 protein (Cdc42/Rac)-activated kinase 7) belongs to the group-2 PAKs and can activate JNK (Jun N-terminus kinase). It contain an amino-termin...


en savoir plus

Votre prix
$542.10 10UG

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

PAK7 (p21 protein (Cdc42/Rac)-activated kinase 7) belongs to the group-2 PAKs and can activate JNK (Jun N-terminus kinase). It contain an amino-terminal CDC42 (cell division cycle 42)/RAC (AKT1, v-akt murine thymoma viral oncogene homolog 1) interactive domain and a carboxyl terminal kinase domain. It plays an important role in outgrowth of neuron cells and synaptic vesicle trafficking. In mice, absence of PAK7 and PAK6 causes learning and locomotion defects. It is mainly expressed in brain. However, it is also considered as an oncogene because of its expression in colorectal, esophageal and gastric cancers.

Legal Information

PRECISIO is a registered trademark of Sigma-Aldrich Co. LLC

Physical form

Supplied in 50 mM Tris-HCl, pH 7.5, with 150 mM NaCl, 0.2 5mM DTT, 0.1 mM EGTA, 0.1 mM EDTA, 0.1 mM PMSF, and 25% glycerol.

assay≥70% (SDS-PAGE)
formbuffered aqueous glycerol solution
Gene Informationhuman ... PAK7(57144)
mol wt~130 kDa
product linePRECISIO® Kinase
Quality Level200
recombinantexpressed in baculovirus infected Sf9 cells
relevant disease(s)cancer
shipped indry ice
specific activity47-63 nmol/min·mg
storage temp.−70°C
UniProt accession no.Q9P286
Ce produit répond aux critères suivants: